Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIM0610 in advanced solid tumors
NCT07348211Phase 1Recruiting
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of SIM0610 in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), head and neck squamous cell carcinoma (HNSCC) and 2 more (2 arms), sponsored by Simcere Pharmaceutical Group. Primary endpoints: Dose Limiting Toxicity at 21 days, Safety and Tolerability and 1 more. Started Jan 2026; status: recruiting.
02
Drugs
SIM0610
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)head and neck squamous cell carcinoma (HNSCC)hepatocellular carcinoma (HCC)solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07348211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07348211.